Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTXT4D5)

• DTT Name: Bacterial Cell membrane (Bact CM)
• Gene Name: Bact CM
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T82349

Molecular Interaction Atlas (MIA) of This DTT

4 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[1]
Delamanid	DMXE76K	Multi-drug resistant tuberculosis	MG52.00	Approved	[2]
Diphtheria-tetanus vaccine	DM0FSIM	Clostridium infection	1A04	Approved	[3]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[4]

7 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
D2A21	DMYJ2QB	Burn and burn infection	ND90-NE2Z	Phase 3	[5]
Brilacidin	DMXI9BP	Acute bacterial skin infection	1C41	Phase 2	[6]
DPK-060	DM059CZ	Atopic dermatitis	EA80	Phase 2	[7]
LTX-109	DMXEQ0R	Bacterial infection	1A00-1C4Z	Phase 2	[8]
Friulimicin	DMUI8F3	Bacterial infection	1A00-1C4Z	Phase 1	[9]
IDR-1018	DM1RNT7	Bacterial infection	1A00-1C4Z	Phase 1	[10]
Lotilibcin	DMDLTCU	Bacterial infection	1A00-1C4Z	Phase 1	[11]

4 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EREMOMYCIN	DMYR5OX	Bacterial infection	1A00-1C4Z	Discontinued in Phase 2	[12]
CB-182804	DMYCPF9	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[13]
BMS-181184	DM1Y75C	Fungal infection	1F29-1F2F	Terminated	[14]
Ro-25-6833	DM07ZSC	Bacterial infection	1A00-1C4Z	Terminated	[15]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
• [3] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
• [6] Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
• [7] The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29.
• [8] A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
• [9] Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
• [10] Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.
• [11] Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287.
• [12] Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics. J Med Chem. 2003 Mar 27;46(7):1204-9.
• [13] Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist. 2012 Apr;18(2):132-6.
• [14] Antifungal Activity of the Pradimicin Derivative BMS 181184 in the Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob Agents Chemother. 1998 September; 42(9): 2399-2404.
• [15] Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J Pharm Sci. 1998 Apr;87(4):496-500.